The main difference is that BCRX has a listing on the Nasdaq rather than the OTC market. The Nasdaq seems to quickly price in new information, especially clinical trial results.
I would expect some positive reaction initially if Phase III is positive, but 40% is unlikely. A license deal for the ROW is more likely to attract massive revaluation from the Aussie market (as is a potential HRV license). Only my gut feel though...
- Forums
- ASX - By Stock
- BTA
- future earnings now take over mcap
future earnings now take over mcap, page-55
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)